Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy There are currently no therapies ...

Operator: Good afternoon, and welcome to the Aethlon Medical Fourth Quarter Fiscal 2025 Earnings and Corporate Update ...

New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of antibiotic resistance through rapid vaccine development.

Again.Marvel and DC will go head-to-head once more in the summer box office, just as both of the comic book movie companies ...

Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox.